Biomarkers: optimizing treatment guidance in heart failure. - Wikidata - awgldk - TriplyDB

Biomarkers: optimizing treatment guidance in heart failure.

Biomarkers: optimizing treatment guidance in heart failure.

http://www.wikidata.org/entity/Q37903747

about

Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.Right ventricular hypertrophy after atrial switch operation: normal adaptation process or risk factor? A cardiac magnetic resonance study.Trends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010 Assessment of a multimarker strategy for prediction of mortality in older heart failure patients: a cohort study.A modified approach to induce predictable congestive heart failure by volume overload in rats.Clinical use of novel biomarkers in heart failure: towards personalized medicine.Chronic exposure to water-pipe smoke induces cardiovascular dysfunction in mice.Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.Labeling galectin-3 for the assessment of myocardial infarction in rats.Optimizing clinical use of biomarkers in high-risk acute heart failure patients.To ascertain the utility of urinary methyl malonic Acid as a potential marker of ischemic heart failure.Pro-thrombotic condition in a woman with peripartum cardiomyopathy treated with bromocriptine and an Impella LP 2.5 heart pump.Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study.Atrial standstill in a patient with progressive severe heart failure.[Diastolic heart failure: heart failure with preserved ejection fraction].Angiographic score assessment improves cardiovascular risk prediction: the clinical value of SYNTAX and Gensini application.Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure.B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events--the Heinz Nixdorf Recall Study.Associates of an elevated natriuretic peptide level in stable heart failure patients: implications for targeted management.

P2860

Q36035702-26747A62-9886-4866-8BAA-C78F4EFE0375 Q36408313-BECCE9A2-5ED9-4D26-8FA5-5B9019AE267C Q36423616-BB682EF1-031F-4BA3-89B2-7CE4C3127C1C Q36730110-AE8CE6FB-70E5-4BB0-AE4F-3AFBBA026635 Q37538767-00186E45-2BBB-47AB-AB5B-E9D29808C1DC Q38109588-3D442678-F693-42EC-9C02-E57F8E196BD2 Q39111217-6D6DE0D4-E5E8-4DB2-9282-2326C1DEF613 Q40412681-2AA14B83-DF03-4E42-AB44-480A2018E536 Q40792117-779BC9FA-7C6E-4351-BEC6-9A85F532BBDC Q41074638-0496C1F2-3D4D-47B2-A73B-CFCB78B31A61 Q42090185-623C0357-72AE-4CFA-8A10-E3B82984ABBB Q42983296-E1EB17F0-AB52-4EC8-8DED-A56E7EA2317D Q44426645-A056DCB8-1FA9-40BA-AA97-90B1CA235582 Q44594551-40FA0A99-D7D6-4DA9-B584-9D551CD487DE Q44888151-03F90C5B-1237-40EA-8321-E7534D3C738E Q45393684-403FD902-72AB-4164-8798-321AB124DEE3 Q46127915-2645D7F8-3F71-4362-9B6E-3AC0B5F1DD49 Q48920776-B356EB86-95A4-498E-9E18-C30573EE0617 Q48932981-002F14D9-55D4-467A-BB45-747E13FD0232 Q55533888-F297BED6-AEE1-4CEA-8F81-09EF330A04CB

P2860

Biomarkers: optimizing treatment guidance in heart failure.

http://www.wikidata.org/entity/Q37903747

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 July 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Biomarkers: optimizing treatment guidance in heart failure.

@en

Biomarkers: optimizing treatment guidance in heart failure.

@nl

type

label

Biomarkers: optimizing treatment guidance in heart failure.

@en

Biomarkers: optimizing treatment guidance in heart failure.

@nl

prefLabel

Biomarkers: optimizing treatment guidance in heart failure.

@en

Biomarkers: optimizing treatment guidance in heart failure.

@nl

P1433

Q37903747-3C60A55C-283D-46A4-8D5F-F9C8DB7A769D

P1476

Q37903747-3023B500-EF54-4E7B-B3DC-1E775FBFC26E

P2093

Q37903747-1555CA4D-C0FC-4271-95B9-85F66B7C0F8D

Q37903747-226AD007-3BFC-4D89-8686-FEEAF981F544

Q37903747-76D94C2F-C698-45D8-8A97-C99FA3A9327E

Q37903747-A597B025-9A6F-405F-8FEB-065A35B7CE15

Q37903747-BF64233D-B696-43B1-B417-65F45709738B

Q37903747-EE552A00-482A-4992-8F06-C57A8AE440C9

P2860

Q37903747-07DEE134-8CAD-4D41-9F36-A9606A27F53F

Q37903747-0D7BEF4C-EF58-4724-B208-36263869414F

Q37903747-11C70C01-C1DD-4A5B-A523-677DCAA21744

Q37903747-1CDA85D9-6E6E-4E3C-B040-CB75B3F62381

Q37903747-1DAFD2DB-67ED-49BC-9682-52955C875E59

Q37903747-28CD2242-33F4-4F3E-BD15-A32CF7383220

Q37903747-2F12C0DC-8693-47D0-B4AB-0C25648328D5

Q37903747-306D56F4-7C77-4150-8807-63D1002C3390

Q37903747-33327AAB-E668-4B48-9AAA-85519B4D9B65

Q37903747-3CFF2F3A-6F18-4ABF-91D5-45187DA5F9B1

P2888

Q37903747-7B252F4D-9143-4928-9C17-B21D5970B587

P304

Q37903747-57C0AA53-6160-42B0-8699-C8634DBAEC00

P31

Q37903747-05FA89F8-EC59-488C-B4CD-7E089B1E2593

P356

Q37903747-15E4113E-9AE0-4D69-8672-B01DBC6913E7

P433

Q37903747-A270043D-9811-44D1-AC3F-CBC804AAA896

P478

Q37903747-2CE8375F-BDCA-478E-87DC-CFC2166A66E3

P50

Q37903747-B76E27BE-4985-4BC4-85CF-D3642A44E3A4

P577

Q37903747-44DF8F4A-ED54-4D87-B3EE-910644B751E1

P698

Q37903747-90CB3FD2-A395-41B9-88F1-A28595FC134A

P921

Q37903747-23FBC9D6-F52B-44B4-A932-1378ACB65791

Q37903747-CAD1BE8D-5916-4711-8830-52756114920C

P356

S00392-011-0341-0

P1433

Clinical Research in Cardiology

P1476

Biomarkers: optimizing treatment guidance in heart failure.

@en

P2093

Adriaan A Voors

http://www.w3.org/2001/XMLSchema#string

Eva Turgonyi

http://www.w3.org/2001/XMLSchema#string

Jean-Marie Ketelslegers

http://www.w3.org/2001/XMLSchema#string

Michael Böhm

http://www.w3.org/2001/XMLSchema#string

Peter Bramlage

http://www.w3.org/2001/XMLSchema#string

Stephan H Schirmer

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

Structure and expression of the human cystatin C gene

Trends in prevalence and outcome of heart failure with preserved ejection fraction

Use of multiple biomarkers to improve the prediction of death from cardiovascular causes

Biomarkers in heart failure

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study.

Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial.

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study.

P2888

s00392-011-0341-0

P304

973-981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00392-011-0341-0

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21779815

http://www.w3.org/2001/XMLSchema#string

P921